BioVest offers cell culture products, instruments, and related contract services to research institutions, biotech firms, and pharmaceutical companies. The company is also developing a therapeutic cancer vaccine for follicular non-Hodgkin's lymphoma that is customized for individual patient use. The candidate, dubbed BiovaxID, is undergoing late-stage clinical trials. Its AutovaxID product is a cell culture instrument designed to ease use of BiovaxID. BioVest is 76% owned by Accentia Biopharmaceuticals. Both BioVest and Accentia filed for Chapter 11 bankruptcy in 2008 and are restructuring their operations.

Lescarden Inc. was founded in 1960 and is based in New York, New York. Lescarden Inc. engages in the research, testing, and development of proprietary biologic materials with a focus on wound healing, clinical skin care, osteoarthritis, and cancer applications. The company offers CATRIX Wound Dressing, a powder derived from bovine cartilage for the management of chronic lesions and burns, as well as for non-healing wounds, such as decubitus ulcers, venous stasis ulcers, and diabetic ulcers. It also provides a line of Catrix-based skin care products for the plastic surgery, dermatology, and medical spa markets. In addition, the company offers nutritional supplements, including BIO-CARTILAGE; and POLY-Nag, a glucosamine polymer for the treatment of osteoarthritis. It also licenses its technologies for commercialization by other companies in Canada, Europe, and Korea. The company sells its products primarily in Europe, the Philippines, and Korea.

TolerRx, Inc. company develops therapies to treat patients with autoimmune diseases, including Type I diabetes and rheumatoid arthritis. Organ transplant rejection is also a target. The company's treatments induce immunological tolerance, or teach a body's immune system to recognize its own tissues and prevent it from attacking the tissue and causing disease. TolerRx has five autoimmune and two cancer/chronic viral drugs in the pipeline. The immune drugs include treatments for Type I diabetes, psoriasis, rheumatoid arthritis, and lupus. TolerRx was founded in 2000 by Herman Waldmann and Douglas J. Ringler.

Morepen Laboratories Limited is an India-based pharmaceutical company. Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin. The Company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast. It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The Company’s subsidiaries include Doctor Morepen Limited, Total Care Limited, Morepen Inc. and MorepenMax Inc.

Merck OY company, a subsidiary of Germany-based Merck KGaA, manufactures, markets, and distributes prescription and over-the-counter pharmaceutical medicines. Merck OY's prescription drugs fall into targeted therapeutic categories such as diabetes, cardiovascular care, and infertility, and its consumer health care segment primarily consists of nutraceutical (vitamin) products. It also makes select chemical products, including liquid crystals and life science laboratory chemicals.

Glycotex wants to see such creatures as ulcers, bed sores, and sunburns put on the Australian endangered species list. The biopharmaceutical company researches and develops products based on molecular glucan receptors that trigger the healing process. Connective tissue repair, skin ulcers, and bone fractures are primary recovery fields for its glucan receptor products. Glycotex's lead product candidate, MG3601, is a topical treatment for ulcers, and it has completed Phase II clinical trials. Other therapeutic candidates include Glucocol and Glucoprime, active ingredients designed to treat tendon regeneration and topical needs, respectively. Its parent company, Novogen, owns 84% of Glycotex.

Founded in 1926, Recordati S.p.A. company makes prescription and nonprescription pharmaceuticals and active pharmaceutical ingredients (APIs). Its prescription drug business includes antibiotics and antiviral drugs, as well as treatments for cardiovascular, central nervous system, dermatological, gynecology, urological, and other disorders and ailments. Over-the-counter products include remedies for allergies and colds, travel sickness, and fungal infections. Recordati company has subsidiaries and direct sales representatives located in about a dozen European countries. Recordati's products are distributed in some 100 countries.

Anacor Pharmaceuticals is a biopharmaceutical company developing novel small-molecule therapeutics derived from its boron chemistry platform to treat infectious and inflammatory diseases. Anacor's most advanced product candidate is AN2690, a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. Anacor also has a portfolio of other topical product candidates in development for the treatment of psoriasis, atopic dermatitis and skin and nail fungal infections. The company has entered into a worldwide license, development and commercialization agreement with Merck for the development and commercialization of AN2690 for all indications including the treatment of onychomycosis. In addition, Anacor has a research and development agreement with GSK for novel antiviral and antibacterial systemic therapeutics.

Since its establishment in 1982, Orgenics' objective has been to develop accurate and safe diagnostic products for serious and life-threatening conditions and diseases. Orgenics contributes to the increased awareness and early detection of HIV, infectious diseases, pregnancy and fertility, respiratory diseases, cancer and cardiology through clinical and point-of-care diagnostics. Orgenics delivers products and solutions to partners and customers in over 150 countries around the globe.Orgenics unique and patented ImmunoComb® technology is quick and easy to use, providing high sensitivity and specificity. Instrument free Orgenics' ImmunoComb® kits are ideal for decentralized clinical laboratories, field hospitals and remote rural areas. Orgenics' ImmunoLISA™ system is based on classic ELISA assay principle and is suitable for any laboratory setting.

APP Pharmaceuticals, a company that develops, makes, and markets anesthetics and other injectable drugs. Specializing in generics, APP's critical care products segment includes market-leading general anesthetic Diprivan and blood thinner Heparin. Other product segments focus on injectable oncology treatments and drugs that fight ear, heart, respiratory tract, skin, and sinus infections. APP markets through a direct sales force and often sells through group purchasing organizations to customers that include hospitals, long-term care facilities, and clinics in North America. APP Pharmaceuticals, LLC company is a subsidiary of German medical firm Fresenius.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.